-continued

```
Cys His Gln Leu Cys Ala Arg Gly His Cys Trp Gly Pro Gly Pro
  1               5                  10                  15

Thr Gln Cys Val Asn Cys Ser Gln Phe Leu Arg Gly Gln Glu Cys
                20                  25                  30

Val Glu Glu Cys Arg Val Leu Gln Gly Leu Pro Arg Glu Tyr Val
                35                  40                  45

Asn Ala Arg His Cys Leu Pro Cys His Pro Glu Cys Gln Pro Gln
                50                  55                  60

Asn Gly Ser Val Thr Cys Phe Gly Pro Glu Ala Asp Gln Cys Val
                65                  70                  75

Ala Cys Ala His Tyr Lys Asp Pro Pro Phe Cys Val Ala Arg Cys
                80                  85                  90

Pro Ser Gly Val Lys Pro Asp Leu Ser Tyr Met Pro Ile Trp Lys
                95                 100                 105

Phe Pro Asp Glu Glu Gly Ala Cys Gln Pro Cys Pro Ile Asn Cys
               110                 115                 120

Thr His Ser Cys Val Asp Leu Asp Asp Lys Gly Cys Pro Ala Glu
               125                 130                 135

Gln Arg Ala Ser Pro Leu Thr
               140
```

What is claimed is:

1. A method for extending time to disease progression (TTP) or survival in cancer patients with metastatic breast cancer which displays HER activation comprising: (a) administering a HER2 antibody which comprises the variable light and variable heavy amino acid sequences in SEQ ID Nos. 3 and 4 as fixed doses of 420 mg to the patients and (b) measuring TTP or survival in the patients to confirm it is extended.

2. The method of claim **1** wherein the HER2 antibody inhibits HER heterodimerization.

3. The method of claim **1** wherein the cancer displays HER2 activation.

4. The method of claim **3** wherein the cancer displays HER2 overexpression or amplification.

5. The method of claim **1** wherein the HER2 antibody is pertuzumab.

6. The method of claim **1** wherein the HER2 antibody is a naked antibody.

7. The method of claim **1** wherein the HER2 antibody is an intact antibody.

8. The method of claim **1** wherein the HER2 antibody is an antibody fragment comprising an antigen binding region.

9. The method of claim **1** wherein the HER2 antibody is administered as a single anti-tumor agent.

10. The method of claim **1** comprising administering a second therapeutic agent to the patients.

11. The method claim **10** wherein the second therapeutic agent is selected from the group consisting of chemotherapeutic agent, HER antibody, antibody directed against a tumor associated antigen, anti-hormonal compound, cardioprotectant, cytokine, EGFR-targeted drug, anti-angiogenic agent, tyrosine kinase inhibitor, COX inhibitor, non-steroidal anti-inflammatory drug, farnesyl transferase inhibitor, antibody that binds oncofetal protein CA 125, HER2 vaccine, HER targeting therapy, Raf or ras inhibitor, liposomal doxorubicin, topotecan, taxane, dual tyrosine kinase inhibitor, TLK286, EMD-7200, a medicament that treats nausea, a medicament that prevents or treats skin rash or standard acne therapy, a medicament that treats or prevents diarrhea, a body temperature-reducing medicament, and a hematopoietic growth factor.

12. The method of claim **10** wherein the second therapeutic agent comprises trastuzumab.

13. The method of claim **1** wherein TTP is extended.

14. The method of claim **1** wherein survival is extended.

15. The method of claim **1** wherein administration of the HER2 antibody extends TTP or survival at least about 20% more than TTP or survival achieved by administering an approved anti-tumor agent to the cancer patients.

16. A method for extending time to disease progression (TTP) or survival in breast cancer patients comprising: (a) administering a HER2 antibody to the patients as fixed doses of about 420 mg of the HER2 antibody so as to extend TTP or survival in the patients, wherein the HER2 antibody comprises the variable light and variable heavy amino acid sequences in SEQ ID Nos. 3 and 4, respectively, and (b) measuring TTP or survival in the patients to confirm it is extended.

17. The method of claim **16** which extends TTP.

18. The method of claim **16** which extends survival.

19. The method of claim **16** wherein the patients are metastatic breast cancer patients.

20. The method of claim **19** wherein the cancer displays HER2 activation.

21. The method of claim **20** wherein the cancer displays amplified or overexpressed HER2.

22. The method of claim **16** wherein the fixed doses of about 420 mg of the HER2 antibody are administered about every three weeks.

23. The method of claim **22** wherein a loading dose of 840 mg of the HER2 antibody is administered followed by the fixed doses of about 420 mg of the HER2 antibody.

24. The method of claim **16** comprising administering a second therapeutic agent to the patients.

25. The method of claim **24** wherein the second therapeutic agent comprises trastuzumab.